It could be OncoImmune was so close to full enrollment they decided to hold off for full trial results.
The effect of OncoImmune's drug is NF-kB inhibition and they had great results. Leronlimab also inhibits NF-kB and does more.
(0)
(0)
CytoDyn Inc (CYDY) Stock Research Links
-
-
-
-
-
-
-
